WeightWatchers has filed for bankruptcy in the US as it struggles with debt and fierce competition from fat-loss jabs like Ozempic and Mounjaro. The legal process will see $1.15 billion of the 60-year-old diet brand’s debt written off while it agrees new terms for paying back its lenders.
WeightWatchers said it will remain “fully operational” during the process with “no impact to members”. It follows the meteoric rise in popularity of weight-loss injections in what the firm said was a “rapidly changing weight management landscape”.
“For more than 62 years, WeightWatchers has empowered millions of members to make informed, healthy choices, staying resilient as trends have come and gone,” said chief executive Tara Comonte. She added that the plans have “the overwhelming support of our lenders.”
The brand said its weight-loss programme, telehealth scheme, and workshops will continue uninterrupted. It vowed that it was “here to stay” and that it was not going out of business.
WeightWatchers reported a net loss of $346 million last year and a 5.6% fall in subscription revenues. In Q1 2025, subscriptions fell a further 9.3%, though its clinical business covering medication delivery grew revenue by over 57%. With total liabilities of $1.88 billion exceeding its assets, the company expects its reorganization plan to be confirmed within 40 days and to emerge as a publicly traded entity.
.webp)
